Renal Cancer
Evolution of cell therapy for renal cell carcinoma.
January 11, 2024
CD70 is Consistently Expressed in Primary and Metastatic Clear Cell Renal Cell Carcinoma.
January 11, 2024
Chronic thrombotic microangiopathy presenting as acute nephrotic syndrome in a patient with renal cancer receiving tyrosine kinase inhibitor therapy.
January 10, 2024
Relapsing cytokine release syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab and axitinib therapy.
January 10, 2024
Understanding Factors that Influence Prognosis and Response to Therapy in Clear Cell Renal Cell Carcinoma.
January 9, 2024
Effects of Purine Metabolism-Related LINC01671 on Tumor Heterogeneity in Kidney Renal Clear Cell Carcinoma.
January 8, 2024
Genomic Fabrics of the Excretory System's Functional Pathways Remodeled in Clear Cell Renal Cell Carcinoma.
January 5, 2024
Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors.
January 5, 2024
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
January 5, 2024
Discontinuation of Immune-oncology Combinations due to Immune-related Adverse Events in Patients With Advanced Renal Cancers.
January 4, 2024
Integration of bioinformatics analysis to identify possible hub genes and important pathways associated with clear cell renal cell carcinoma.
January 4, 2024
Papillary Renal Cell Carcinoma: Demographics, Survival Analysis, Racial Disparities, and Genomic Landscape.
January 3, 2024